Technologies

Voice biomarkers

BioSensics provides devices and digital technologies for collection and analysis of speech data during site visits and at predefined frequencies in the home environment.

BioSensics technologies are currently being used in NIH-funded studies in Alzheimer’s and Huntington’s diseases, and also phase 0 studies in multiple system atrophy and amyotrophic lateral sclerosis.

BioSensics has early-stage development programs in objective and automatic assessment of dysarthria and disease-specific speech problems.